Search
Biospace news
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 11 hours 38 min ago
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree 4/26/2024
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results 4/26/2024
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1
BMS to Cut 2,200 Jobs in $1.5B Restructuring as Opdivo Sales Drop in Q1 4/25/2024
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20%
Merck Gets Q1 Beat as Sales of Cancer Blockbuster Keytruda Jump 20% 4/25/2024
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy
Sanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy 4/25/2024
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery 4/25/2024
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1
Sanofi and AstraZeneca Scrap Several Early-Stage Programs in Q1 4/25/2024
FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier
FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier 4/25/2024
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women 4/25/2024
7 Types of Difficult Bosses and How to Deal With Them
7 Types of Difficult Bosses and How to Deal With Them 4/25/2024
Why Biopharma Companies Avoid Hiring People Who Need Visas
Why Biopharma Companies Avoid Hiring People Who Need Visas 4/25/2024
Where Do We Go From Here? The Future of Women's Health
Where Do We Go From Here? The Future of Women's Health 4/25/2024
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales 4/23/2024
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win 4/23/2024
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates 4/23/2024
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC 4/23/2024
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data 4/23/2024
Supreme Court Denies Vanda’s Petition in Hetlioz Patent Case Against Teva
Supreme Court Denies Vanda’s Petition in Hetlioz Patent Case Against Teva 4/23/2024
Alvotech, Teva Enlist New Partner to Expand Access to Humira Biosimilar in US
Alvotech, Teva Enlist New Partner to Expand Access to Humira Biosimilar in US 4/19/2024
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies 4/19/2024
World Pharma News
- Participants of pioneering CRISPR gene editing trial see vision improve
- Drug targeting RNA modifications shows promise for treating neuroblastoma
- Scientists track 'doubling' in origin of cancer cells
- Possible alternative to antibiotics produced by bacteria
- Kaposi sarcoma discovery could facilitate drug development